Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA4 have dramatically improved melanoma treatment—and the LAG3 immune checkpoint inhibitor relatlimab may soon be added to the mix. In a phase III trial, adding relatlimab to the PD-1 inhibitor nivolumab more than doubled progression-free survival, and the combination had relatively manageable side effects.

You do not currently have access to this content.